Soto-Matos A - Search Results

1

Phase I dose-escalation study of plitidepsin in combination with sorafenib or gemcitabine in patients with refractory solid tumors or lymphomas.

Aspeslagh S, Stein M, Bahleda R, Hollebecque A, Salles G, Gyan E, Fudio S, Extremera S, Alfaro V, Soto-Matos A, Soria JC. Aspeslagh S, et al. Among authors: soto matos a. Anticancer Drugs. 2017 Mar;28(3):341-349. doi: 10.1097/CAD.0000000000000457. Anticancer Drugs. 2017. PMID: 27977433 Clinical Trial.

2

Plitidepsin has a safe cardiac profile: a comprehensive analysis.

Soto-Matos A, Szyldergemajn S, Extremera S, Miguel-Lillo B, Alfaro V, Coronado C, Lardelli P, Roy E, Corrado CS, Kahatt C. Soto-Matos A, et al. Mar Drugs. 2011;9(6):1007-1023. doi: 10.3390/md9061007. Epub 2011 Jun 9. Mar Drugs. 2011. PMID: 21747745 Free PMC article. Clinical Trial.

3

Phase I and pharmacokinetic study of sequential paclitaxel and trabectedin every 2 weeks in patients with advanced solid tumors.

Chu Q, Mita A, Forouzesh B, Tolcher AW, Schwartz G, Nieto A, Soto-Matos A, Alfaro V, Lebedinsky C, Rowinsky EK. Chu Q, et al. Clin Cancer Res. 2010 May 1;16(9):2656-65. doi: 10.1158/1078-0432.CCR-10-0062. Epub 2010 Apr 20. Clin Cancer Res. 2010. PMID: 20406837 Clinical Trial.

4

Spisulosine (ES-285) given as a weekly three-hour intravenous infusion: results of a phase I dose-escalating study in patients with advanced solid malignancies.

Schöffski P, Dumez H, Ruijter R, Miguel-Lillo B, Soto-Matos A, Alfaro V, Giaccone G. Schöffski P, et al. Cancer Chemother Pharmacol. 2011 Dec;68(6):1397-403. doi: 10.1007/s00280-011-1612-1. Epub 2011 Apr 5. Cancer Chemother Pharmacol. 2011. PMID: 21465314 Clinical Trial.

5

First-in-man phase I trial of two schedules of the novel synthetic tetrahydroisoquinoline alkaloid PM00104 (Zalypsis) in patients with advanced solid tumours.

Yap TA, Cortes-Funes H, Shaw H, Rodriguez R, Olmos D, Lal R, Fong PC, Tan DS, Harris D, Capdevila J, Coronado C, Alfaro V, Soto-Matos A, Fernández-Teruel C, Siguero M, Tabernero JM, Paz-Ares L, de Bono JS, López-Martin JA. Yap TA, et al. Among authors: soto matos a. Br J Cancer. 2012 Apr 10;106(8):1379-85. doi: 10.1038/bjc.2012.99. Br J Cancer. 2012. PMID: 22491421 Free PMC article. Clinical Trial.

6

Trabectedin has a low cardiac risk profile: a comprehensive cardiac safety analysis.

Lebedinsky C, Gómez J, Park YC, Nieto A, Soto-Matos A, Parekh T, Alfaro V, Roy E, Lardelli P, Kahatt C. Lebedinsky C, et al. Cancer Chemother Pharmacol. 2011 Nov;68(5):1223-31. doi: 10.1007/s00280-011-1614-z. Epub 2011 Mar 18. Cancer Chemother Pharmacol. 2011. PMID: 21416137 Clinical Trial.

7

Phase I and pharmacokinetic study of trabectedin 3-hour infusion every three weeks in patients with advanced cancer and alteration of hepatic function.

Pardo B, Salazar R, Ciruelos E, Cortés-Funes H, García M, Majem M, Montes A, Cuadra C, Soto-Matos A, Lebedinsky C, Alfaro V, Paz-Ares L. Pardo B, et al. Med Oncol. 2012 Sep;29(3):2240-50. doi: 10.1007/s12032-011-9979-8. Epub 2011 Jun 10. Med Oncol. 2012. PMID: 21660618 Clinical Trial.

8

Multicenter Phase II Study of Lurbinectedin in BRCA-Mutated and Unselected Metastatic Advanced Breast Cancer and Biomarker Assessment Substudy.

Cruz C, Llop-Guevara A, Garber JE, Arun BK, Pérez Fidalgo JA, Lluch A, Telli ML, Fernández C, Kahatt C, Galmarini CM, Soto-Matos A, Alfaro V, Pérez de la Haza A, Domchek SM, Antolin S, Vahdat L, Tung NM, Lopez R, Arribas J, Vivancos A, Baselga J, Serra V, Balmaña J, Isakoff SJ. Cruz C, et al. Among authors: soto matos a. J Clin Oncol. 2018 Nov 1;36(31):3134-3143. doi: 10.1200/JCO.2018.78.6558. Epub 2018 Sep 21. J Clin Oncol. 2018. PMID: 30240327 Free PMC article. Clinical Trial.

9

Phase I study of weekly plitidepsin as 1-hour infusion combined with carboplatin in patients with advanced solid tumors or lymphomas.

Salazar R, Plummer R, Oaknin A, Robinson A, Pardo B, Soto-Matos A, Yovine A, Szyldergemajn S, Calvert AH. Salazar R, et al. Invest New Drugs. 2011 Dec;29(6):1406-13. doi: 10.1007/s10637-010-9488-1. Epub 2010 Jul 10. Invest New Drugs. 2011. PMID: 20623160 Clinical Trial.

10

A phase I and pharmacokinetic study of elisidepsin (PM02734) in patients with advanced solid tumors.

Salazar R, Jones RJ, Oaknin A, Crawford D, Cuadra C, Hopkins C, Gil M, Coronado C, Soto-Matos A, Cullell-Young M, Iglesias Dios JL, Evans TR. Salazar R, et al. Among authors: soto matos a. Cancer Chemother Pharmacol. 2012 Nov;70(5):673-81. doi: 10.1007/s00280-012-1951-6. Epub 2012 Aug 25. Cancer Chemother Pharmacol. 2012. PMID: 22926637 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

21 results

Search Page